Ocugen Inc (OCGN)
$0.28 0.00 (0.18%)
14:17 EDT OCGN Stock Quote Delayed 20 Minutes
Previous Close $0.28
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 739,208
Day's Range 0.28 - 0.29
52-Week Range 0.24 - 8.62
Dividend & Yield N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
- From InvestorPlace
- From the Web
Even in the best of circumstances, OCGN stock was never for the faint of heart. With the coronavirus raging everywhere, I’m not sure for whom Ocugen is appropriate.
By Thomas Niel
With this in mind, the best bet is to avoid Ocugen stock. Shares could skyrocket if OCU300 shows positive top-line results. Conversely, shares could fall to new lows if results do not match expectations. It may be temping to place a buy order and hope for the best. But, long-term, investing success requires discretion, not speculation. Seek more solid opportunities elsewhere, and put Ocugen on hold for now.
Ocugen stock has fallen far, and needs positive trial results for its OCU300 treatment to turn things around. For now, it's a high-risk play.
By David Moadel
A pipeline of treatments for underserved eye conditions like oGVHD makes OCGN stock worth considering as part of your biotech holdings.
Except for a couple of specific investors, Ocugen stock is not one for average people. Instead, look at Bausch Health Companies, which has a very rocky backstory but has managed to turn the corner.
OCGN stock makes an attractive speculative case because of the underlying company’s potential to address rare eye diseases. Still, this is an opportunity that only risk-takers with “dumb money” should engage.
With two orphan drug designations and a promising partnership, Ocugen stock makes a good play for speculative investors.
How Ocugen stock came to be makes no sense. Neither does the idea that investors will continue to pour money into this cesspool.
Ocugen gave rise to OCGN stock through a reverse merger with Histogenics. But despite this confusing deal, it really didn't do much for either company in the end.
Ocugen (OCGN) news for Wednesday about a massive stock buyback plan for $2 million worth of shares has OCGN stock on the move.
From Analyst Ratings
In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Ocugen (OCGN – Research Report), with a price target of $2.00. The company’s shares closed last Friday at $0.30, close to its 52-week low of $0.24. According to TipRanks.com, Nakae is a 1-star analyst with an average return of -4.5%
Ocugen, Inc. (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. The company’s Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Ocugen’s breakthrough modifier gene therapy platform has the potential to […]
Navellier RatingsPowered by Portfolio Grader